CARM (CARISMA Therapeutics) Pretax Margin %: 98.82% (As of Sep. 2025)

What is CARISMA Therapeutics Pretax Margin %?

CARISMA Therapeutics CARM Pretax Margin % is 98.82% as of Sep. 2025. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, CARISMA Therapeutics ranks better than 83.47% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CARISMA Therapeutics's Pre-Tax Income for the three months ended in Sep. 2025 was $44.72 Mil. CARISMA Therapeutics's Revenue for the three months ended in Sep. 2025 was $45.25 Mil. Therefore, CARISMA Therapeutics's pretax margin for the quarter that ended in Sep. 2025 was 98.82%.

The historical rank and industry rank for CARISMA Therapeutics's Pretax Margin % or its related term are showing as below:

CARM' s Pretax Margin % Range Over the Past 10 Years
Min: -622.6 Med: -582.34 Max: 15.28
Current: 15.28

CARM's Pretax Margin % is ranked better than
83.47% of 944 companies
in the Biotechnology industry
Industry Median: -90.5 vs CARM: 15.28

CARISMA Therapeutics (OTCPK:CARM) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

CARISMA Therapeutics Pretax Margin % Related Terms

CARISMA Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Pretax Margin % Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Pretax Margin %

0.00

-622.60

-582.34

-308.05

CARISMA Therapeutics Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25
Pretax Margin %	Get a 7-Day Free Trial												-375.24	-482.75	-248.48	0.00	98.82

CARM vs SCPX, CYTOF, CNBX: Pretax Margin % Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Pretax Margin % falls into.

Save Embed

CARISMA Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

CARISMA Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-60.477	/	19.632
	=	-308.05 %

CARISMA Therapeutics's Pretax Margin for the quarter that ended in Sep. 2025 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Sep. 2025 )	/	Revenue (Q: Sep. 2025 )
	=	44.717	/	45.25
	=	98.82 %

Frequently Asked Questions Learn more about Pretax Margin % →

What does a Pretax Margin % of 98.82% mean?

CARISMA Therapeutics (CARM) has a Pretax Margin % of 98.82% as of Sep. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #156 out of 944 companies in the Biotechnology industry, placing it in the top 16.5%.

Is CARISMA Therapeutics' Pretax Margin % too high?

CARISMA Therapeutics' current Pretax Margin % is 98.82%. Based on the distribution chart, CARISMA Therapeutics ranks #156 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.

How does CARISMA Therapeutics' Pretax Margin % compare to SCPX and CYTOF?

According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #156 out of 944 companies for Pretax Margin %. This places CARISMA Therapeutics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Pretax Margin % for a Biotechnology company?

A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Pretax Margin % mean?

A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Pretax Margin % is 98.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CARISMA Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Pretax Margin % is 98.82%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Pretax Margin % calculated?

Pretax Margin % is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Pretax Margin % is 98.82% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies SCPX CYTOF CNBX IOBTQ LIPO WINT CERO ENDV RGBP RMTG VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104

Website https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.